首页> 外文期刊>The Open Hypertension Journal >Pharmacogenomics of Adrenergic Receptors; from Hypertension to Heart Failure
【24h】

Pharmacogenomics of Adrenergic Receptors; from Hypertension to Heart Failure

机译:肾上腺素能受体的药物基因组学;从高血压到心力衰竭

获取原文
       

摘要

Cardiovascular medicine is a leading area of pharmacogenomics (PGx). A number of PGx studies have linkedgenetic polymorphisms to patients’ response to the drugs in the pharmacotherapy against cardiovascular diseases. Amongthem, PGx of adrenoceptors is one of the most important fields, because adrenergic networks play important roles in cardiovascularsystems. The excess of adrenergic stimuli result in cardiovascular disorders, such as hypertension and heartfailure (HF). One of the aims of PGx studies of adrenoreceptors is the personalization of β-blocker therapy. In this review,we have described biological and clinical impacts on genetic variants of adrenoreceptors, some of which have showedclear association with the reduction in heart rate and blood pressure in response to β-blockers. Beyond anti-hypertensiontherapy, PGx of adrenoreceptors would contribute to the individualization of pharmacotherapy against HF.
机译:心血管医学是药物基因组学(PGx)的主要领域。许多PGx研究已将遗传多态性与患者对心血管疾病的药物疗法中对药物的反应相关。其中,肾上腺素能受体PGx是最重要的领域之一,因为肾上腺素网络在心血管系统中起着重要的作用。过量的肾上腺素能刺激会导致心血管疾病,例如高血压和心衰(HF)。 PGx肾上腺素受体研究的目的之一是β受体阻滞剂疗法的个性化。在这篇综述中,我们描述了对肾上腺素受体遗传变异的生物学和临床影响,其中一些已显示出与对β受体阻滞剂反应的心率和血压降低明显相关。除了抗高血压疗法外,肾上腺素受体的PGx还将有助于针对HF的药物疗法的个体化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号